Longitudinal Association of Mid-Life Ten Year Cardiovascular Disease Risk Score with Brain Biomarkers of Alzheimer's Disease, Neurodegeneration and White Matter Hyper Intensities in Cognitively Unimpaired Older Adults: Heart SCORE Brain Study
Saeed, A.; Chang, Y.; Swanson, J.; Vu, M.; Mapstone, M.; Villemagne, V. L.; Snitz, B.; Royse, S. K.; Lopresti, B.; Aizenstein, H.; Wu, M.; Kip, K. E.; Reis, S. E.; Lopez, O.; Cohen, A. D.
Show abstract
IntroductionAtherosclerotic cardiovascular disease (ASCVD) risk factors in mid-life have been associated with cognitive decline and late-life dementia. However, the role of these risk factors in preclinical Alzheimers disease (AD) pathophysiology remains elusive. We investigated whether mid-life 10-year pooled cohort equations (PCE) based ASCVD risk is associated with late-life amyloid, tau, neurodegeneration [AT(N)] measures and white matter hyperintensities (WMHI). MethodsParticipants enrolled in the Heart Strategies Concentrating on Risk Evaluation (Heart SCORE) study between 2003-2005 (mid-life) and underwent brain MRI and PET scans in 2018-2022 (age >65 years, late-life) to detect and quantify amyloid (A, PiB-PET) and tau (T, Flortaucipir (FTP) PET) deposition, cortical thickness (N) and white matter hyperintensities (WMHIs). Mid-life PCE ASCVD risk was categorized as; borderline (5%-7.4%), intermediate (7.5%-<15%), or high ([≥]15%). Association of midlife ASCVD risk HR (5% CI) was assessed using logistic and linear regressions with A, T, or N and chi square beta coefficients for WMHI in latelife. ResultsOver a [~]16y follow up, in 135 participants (mean age 73y), A and T showed no significant association with mid-life ASCVD risk. Neurodegeneration had a graded association with mid-life ASCVD risk categories (ORASCVD high vs low risk% 6.98 [2.44-19.95]; p<0.05) driven by self-identified Black race and age. In a subset n=60, ASCVD risk score was also associated with WMHIs (({beta}=0.42 {+/-} 0.22; p=0.05) in a model adjusted for inflammation and education. ConclusionsIn this asymptomatic, diverse cohort, 10y ASCVD risk was predictive of late-life neurodegeneration and white matter hyperintensities but not amyloid or tau. These data suggest that ASCVD risk factors in midlife may lead to a state of vulnerability (through increased neurodegeneration and white matter hyperintensities) which may progress to cognitive decline and dementia. Further mechanistic studies are warranted to test this hypothesis. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=132 SRC="FIGDIR/small/24301752v1_ufig1.gif" ALT="Figure 1"> View larger version (22K): org.highwire.dtl.DTLVardef@3e2dbborg.highwire.dtl.DTLVardef@2c867borg.highwire.dtl.DTLVardef@13101a3org.highwire.dtl.DTLVardef@627e2c_HPS_FORMAT_FIGEXP M_FIG C_FIG
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Plasma biomarkers identify brain ATN abnormalities in a dementia-free population-based cohort 96%
- TREM2 Risk Variants with Alzheimer’s Disease Differ in Rate of Cognitive Decline 96%
- Assessment of the relationship between synaptic density and metabotropic glutamate receptors in early Alzheimer's disease: a multi-tracer PET study 96%
Similar papers in this journal
- CSF Aβ38 levels are associated with Alzheimer-related decline: implications for γ-secretase modulators 96%
- Susceptibility to postmortem (co)-pathologies in antemortem atrophy-based subtypes of Alzheimer’s disease 94%
- Physical activity and risk of Alzheimer’s disease: a two-sample Mendelian randomization study 93%
Similar papers in this journal
- Blood pressure variability, central autonomic network dysfunction and cerebral small vessel disease in APOE4 carriers 94%
- Chromosome 10q24.32 Variants Associate with Brain Arterial Diameters in Diverse Populations: A Genome-Wide Association Study 93%
- Trajectories of Cognitive Decline Before and After New-onset Hypertension 92%
Similar papers in this journal
- Peripheral inflammation is associated with structural brain atrophy and cognitive decline linked to mild cognitive impairment and Alzheimer's disease 97%
- PTPRS is a novel marker for early tau pathology and synaptic integrity in Alzheimer's disease 96%
- A FinnGen pilot clinical recall study for Alzheimer’s disease 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.